Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension

Stuart Isaacson, Steven Vernino, Adam Ziemann, Gerald J. Rowse, Uwa Kalu, William B. White

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The long-term safety of droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Parkinson disease, pure autonomic failure, multiple system atrophy, or nondiabetic autonomic neuropathy was evaluated in a phase 3, multinational, open-label study in patients who previously participated in a double-blind, placebo-controlled clinical trial of droxidopa. A total of 350 patients received droxidopa 100 to 600 mg three times daily. Mean duration of droxidopa exposure was 363 days (range, 2–1133 days). Rates of serious adverse events (AEs), cardiac-related AEs, and supine hypertension were 24%, 5%, and 5%, respectively. Most AEs, including those of a cardiovascular nature, were not attributed by investigators to droxidopa. In this large cohort of patients with neurogenic orthostatic hypotension, droxidopa was well tolerated during long-term use.

Original languageEnglish (US)
Pages (from-to)755-762
Number of pages8
JournalJournal of the American Society of Hypertension
Volume10
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Droxidopa
Orthostatic Hypotension
Safety
Pure Autonomic Failure
Multiple System Atrophy
Controlled Clinical Trials
Parkinson Disease
Placebos
Research Personnel
Hypertension

Keywords

  • Supine hypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension. / Isaacson, Stuart; Vernino, Steven; Ziemann, Adam; Rowse, Gerald J.; Kalu, Uwa; White, William B.

In: Journal of the American Society of Hypertension, Vol. 10, No. 10, 01.10.2016, p. 755-762.

Research output: Contribution to journalArticle

Isaacson, Stuart ; Vernino, Steven ; Ziemann, Adam ; Rowse, Gerald J. ; Kalu, Uwa ; White, William B. / Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension. In: Journal of the American Society of Hypertension. 2016 ; Vol. 10, No. 10. pp. 755-762.
@article{653a83252411461a9c72e00ccea66ee9,
title = "Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension",
abstract = "The long-term safety of droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Parkinson disease, pure autonomic failure, multiple system atrophy, or nondiabetic autonomic neuropathy was evaluated in a phase 3, multinational, open-label study in patients who previously participated in a double-blind, placebo-controlled clinical trial of droxidopa. A total of 350 patients received droxidopa 100 to 600 mg three times daily. Mean duration of droxidopa exposure was 363 days (range, 2–1133 days). Rates of serious adverse events (AEs), cardiac-related AEs, and supine hypertension were 24{\%}, 5{\%}, and 5{\%}, respectively. Most AEs, including those of a cardiovascular nature, were not attributed by investigators to droxidopa. In this large cohort of patients with neurogenic orthostatic hypotension, droxidopa was well tolerated during long-term use.",
keywords = "Supine hypertension",
author = "Stuart Isaacson and Steven Vernino and Adam Ziemann and Rowse, {Gerald J.} and Uwa Kalu and White, {William B.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.jash.2016.07.010",
language = "English (US)",
volume = "10",
pages = "755--762",
journal = "Journal of the American Society of Hypertension",
issn = "1933-1711",
publisher = "Elsevier Ireland Ltd",
number = "10",

}

TY - JOUR

T1 - Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension

AU - Isaacson, Stuart

AU - Vernino, Steven

AU - Ziemann, Adam

AU - Rowse, Gerald J.

AU - Kalu, Uwa

AU - White, William B.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The long-term safety of droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Parkinson disease, pure autonomic failure, multiple system atrophy, or nondiabetic autonomic neuropathy was evaluated in a phase 3, multinational, open-label study in patients who previously participated in a double-blind, placebo-controlled clinical trial of droxidopa. A total of 350 patients received droxidopa 100 to 600 mg three times daily. Mean duration of droxidopa exposure was 363 days (range, 2–1133 days). Rates of serious adverse events (AEs), cardiac-related AEs, and supine hypertension were 24%, 5%, and 5%, respectively. Most AEs, including those of a cardiovascular nature, were not attributed by investigators to droxidopa. In this large cohort of patients with neurogenic orthostatic hypotension, droxidopa was well tolerated during long-term use.

AB - The long-term safety of droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Parkinson disease, pure autonomic failure, multiple system atrophy, or nondiabetic autonomic neuropathy was evaluated in a phase 3, multinational, open-label study in patients who previously participated in a double-blind, placebo-controlled clinical trial of droxidopa. A total of 350 patients received droxidopa 100 to 600 mg three times daily. Mean duration of droxidopa exposure was 363 days (range, 2–1133 days). Rates of serious adverse events (AEs), cardiac-related AEs, and supine hypertension were 24%, 5%, and 5%, respectively. Most AEs, including those of a cardiovascular nature, were not attributed by investigators to droxidopa. In this large cohort of patients with neurogenic orthostatic hypotension, droxidopa was well tolerated during long-term use.

KW - Supine hypertension

UR - http://www.scopus.com/inward/record.url?scp=84992127887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992127887&partnerID=8YFLogxK

U2 - 10.1016/j.jash.2016.07.010

DO - 10.1016/j.jash.2016.07.010

M3 - Article

C2 - 27614923

AN - SCOPUS:84992127887

VL - 10

SP - 755

EP - 762

JO - Journal of the American Society of Hypertension

JF - Journal of the American Society of Hypertension

SN - 1933-1711

IS - 10

ER -